

CONTENTS

| | |
|--|-----------|
| Jonathan Berman <i>Partner, Jones Day</i> <i>HELPING FOOD COMPANIES AVOID AND DEFEND AGAINST PRODUCT MISLABELING CLASS ACTIONS</i> | 7 |
| Kevin M. Nelson <i>Partner, Duane Morris LLP</i> <i>WHAT YOU NEED TO KNOW TO PLAY THE PHARMACEUTICAL PATENT LITIGATION GAME: BEST PRACTICES, EMERGING TRENDS, AND CHANGES IN THE GENERIC DRUG AND BIOSIMILARS WORLD</i> | 15 |
| Michael F. Ruggio <i>Shareholder, LeClair Ryan</i> <i>MORE PRODUCTS AND ISSUES, FEWER FDA RESOURCES</i> | 33 |
| Reed D. Rubinstein <i>Partner, Dinsmore & Shohl LLP</i> <i>DEFENDING WHAT MATTERS: EFFECTIVELY HANDLING FOOD AND DRUG CLAIMS IN A DYNAMIC REGULATORY AND PUBLIC RELATIONS ENVIRONMENT</i> | 45 |
| Van H. Beckwith <i>Partner, Baker Botts LLP</i> <i>LITIGATING FOOD AND BEVERAGE LABELING CASES: SOME STRATEGIES AND TRENDS</i> | 67 |

| | |
|--|------------|
| Felicia Leborgne Nowels <i>Shareholder, Akerman Senterfitt</i> CURRENT PREEMPTION ISSUES IN FDA LITIGATION: WHAT'S A MANUFACTURER TO DO? FOLLOW THE LAW—BUT PAY CLOSE ATTENTION TO FUTURE CHANGES IN THE LAW | 89 |
| Lorraine E.J. Gallagher <i>Partner, Wilson Elser Moskowitz Edelman & Dicker LLP</i> FDA-APPROVED PRODUCTS: STRATEGIES FOR DEFENDING A RECALLED PRODUCT | 105 |
| Daniel S. Wittenberg <i>Partner, Snell & Wilmer LLP</i> IMPACTS OF THE FDASIA AND RECENT FOOD AND DRUG LAW LITIGATION | 119 |
| Bruce S. Manheim Jr. <i>Partner, Wilmer Cutler Pickering Hale and Dorr LLP</i> A PRIMER: RECENT DEVELOPMENTS AND STRATEGIES IN PETITIONS AND LAWSUITS CHALLENGING FDA APPROVAL OF GENERIC DRUG PRODUCTS UNDER THE ADMINISTRATIVE PROCEDURE ACT | 145 |